Gilead Sciences Inc.’s submission of its HIV therapy elvitegravir to FDA, announced late June 27, could mean the beginning of competition in the integrase inhibitor field – and offer the first once-daily option.
Gilead Files Once-Daily Integrase Inhibitor Elvitegravir With FDA
Part of the Quad combination product, stand-alone elvitegravir could open up the integrase inhibitor market. In a study supporting the single-agent NDA, once-daily elvitegravir proved comparable to Merck’s twice-daily blockbuster Isentress, the only commercially available integrase inhibitor.